Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to ...

Methods Pooled data from bio-naïve patients with active PsA receiving guselkumab 100 mg every 8/4 weeks were retrospectively analysed. Non-negative matrix factorisation was applied as an unsupervised ...

Subcutaneous guselkumab showed significant clinical remission and endoscopic response in moderate to severe Crohn's disease, with no added safety concerns. The GRAVITI study supported guselkumab's ...

Treatment with guselkumab in patients with plaque psoriasis was associated with improvements in 3 biomarkers, yet greater improvements were seen with adalimumab and similar improvements were seen with ...

No significant differences were observed with guselkumab treatment long-term among patients with psoriasis at high-risk for liver fibrosis vs those at low-risk for liver fibrosis or across age groups.

Janssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for guselkumab (Tremfya) to treat Crohn's disease and ulcerative colitis (UC).

Johnson & Johnson (J&J) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its dual-acting IL-23 inhibitor Tremfya (guselkumab) in Crohn’s disease (CD) and ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya, Janssen-Cilag Limited) for use in adults with Crohn’s disease and ulcerative colitis (UC).

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted on 16th May, 2025 to ...